



**Canadian
Cardiovascular
Society**

MYCOVACC

The CCS National Active Surveillance Study of **MY**ocarditis and/or Pericarditis following mRNA **COVID-19 VACC**ination (MYCOVACC) is a multi-centre, pan-Canadian study funded by the Public Health Agency of Canada.

\$1.6M Awarded to MYCOVACC for Fourth Year of Study into COVID-19 and mRNA Vaccines



**Canadian
Cardiovascular
Society**

MYCOVACC

**Canadian Cardiovascular
Society Secures \$1.6M for
Fourth Year of Major
National Surveillance
Study Into COVID-19 and
mRNA Vaccines**



New funding from the Public Health Agency of Canada will allow the national study to continue at more than 30 sites across Canada. Funds will be used to support the expanded study of adults and children with myocarditis and/or pericarditis after mRNA COVID-19 vaccination or infection, and to create tools and resources for healthcare

professionals, policymakers, and the public to help inform decision-making about vaccines. This brings the total funding for the MYCOVACC Study to \$6.6M.

[Read the News Release Here](#)

Study Update

MYCOVACC has recruited over 35 study sites across Canada with assistance from our key research partner networks. Recruitment is approaching 500 patients with post-vaccine myocarditis. A key sub-study focused on convalescent cardiac magnetic resonance imaging and patch arrhythmia monitoring has started.

The MYCOVACC team provided an update on study progress at the Public Health Agency of Canada Knowledge Sharing Event on November 6, 2024.

New Committees

Two new MYCOVACC committees will guide the study's knowledge translation and scientific and data management activities.

The MYCOVACC **Integrated Knowledge Translation Committee** will develop and support knowledge translation strategies and activities. Members will ensure knowledge products meet the needs of the project's key audiences.

[Explore the Committee Member Profiles Here](#)

The MYCOVACC **Scientific and Data Management Committee** will ensure high-quality data, and ethical data collection, storage, and use. The Committee will review and make recommendations to the Steering Committee about all protocols, publications, and reports.

[Explore the Committee Member Profiles Here](#)

Listen: Cardio Connector Podcast Episode - Myocarditis & Pericarditis after mRNA COVID-19 Vaccination: New Clinical Resources

In this podcast, Dr. Michael McDonald discusses new CCS clinical resources about post-vaccine myocarditis and pericarditis. You can access the podcast [here](#).



CARDIO
CONNECTOR

A CANADIAN CARDIOVASCULAR SOCIETY
PODCAST

Learn: Two New Courses on COVID-19 Now Available on CardioCampus

You can now access two MYCOVACC continuing professional development resources from the new CCS CardioCampus platform. If you are not a CCS member or don't yet have a my.ccs.ca guest account, you can open one [now](#).

Section 3 Course: Status and Management Update on Myocarditis and Pericarditis after mRNA COVID-19 Vaccination (2024)

Myocarditis and
Pericarditis after mRNA
COVID-19 Vaccination



This CCS online MOC Section 3 accredited self-assessment program provides an update on myocarditis and pericarditis after mRNA COVID-19 vaccination from public health, cardiology, and family medicine perspectives. Dr. Anil Gupta chairs the session. Panelists are Dr. Daisy de la Cruz Davalos, Dr. Nathaniel Hawkins, Dr. Tahir Kafil, Dr. Alexander Singer and Dr. Tonja Stothart.

[Access the Course Here](#)

Recording: Unmasking the Cardiac Legacy of COVID-19: Insights and Impacts in 2025

This CCS MOC Section 2 webinar recording addresses the acute and chronic cardiovascular effects of COVID-10 infection as well as the benefits and risks associated with mRNA COVID-19 vaccination. Experts critically assess emerging

Recorded
Program



2025

evidence, equipping clinicians with knowledge to support patient care and counselling. Dr. Anil Gupta chairs the session. Panelists are Dr. Nathaniel Hawkins, Dr. Thao Huynh, Dr Naveed Janjua, and Dr. Satish Raj.

[Access the Recording Here](#)

Visit: Updated MYCOVACC Webpages

We've streamlined access to key information about the MYCOVACC initiative and added member profiles for our two new committees.

[Visit the Updated Webpages Here](#)

Related Research

García HA, Wong S, Jeong D, Binka M, Naveed Z, Wilton J, Hawkins NM, Janjua NZ. Risk of major adverse cardiovascular events after SARS-coV-2 infection in British Columbia: A population-based study. *The American Journal of Medicine*. 2025 Mar 1;138(3):524-31.

<https://doi.org/10.1016/j.amjmed.2024.04.010>

Email: mycovacc@ccs.ca

Website: <https://ccs.ca/mycovacc/>

Financial contribution from



Public Health
Agency of Canada

Agence de la santé
publique du Canada



[Please click here to opt out of this mailing or to change your CCS communication preferences.](#)

[Unsubscribe](#) | [Constant Contact Data Notice](#)